


EULAR 2026 Preview – Clinical and AI / ML



LucidQuest Intelligence
Accelerate your success



EULAR 2026 Preview – Table of Contents

• <u>New Trends in Oncology Treatment Strategy At EULAR'26</u>	<u>3-5</u>
• <u>Key Sessions To Watch</u>	<u>6-7</u>
• <u>Industry-sponsored Sessions & Focus Areas At EULAR 2026</u>	<u>8-15</u>
• <u>Competitive Landscape At a Glance at EULAR 2026</u>	<u>9-10</u>
• <u>Key Industry-sponsored Sessions At EULAR 2026</u>	<u>11-15</u>
• <u>New Entrants</u>	<u>16</u>
• <u>AI/ML Trends & Strategic Watchpoints At EULAR 2026</u>	<u>17-20</u>
• <u>AI / DIGITAL HEALTH ANGLE At EULAR 2026</u>	<u>18-19</u>
• <u>What We're Watching For Post-congress</u>	<u>20</u>
• <u>Get In Touch With LucidQuest</u>	<u>21</u>



(1/3)



• **SLE and lupus nephritis will test whether mechanisms translate into organ-level differentiation**

- EULAR 2026 will include nipocalimab in JASMINE-SLE, ianalumab in SLE after B-cell recovery, obinutuzumab histological remission in REGENCY lupus nephritis, enpatoran WILLOW extension data, daratumumab in treatment-refractory SLE, and anifrolumab real-world ASTER analyses. The focus will examine whether FcRn blockade, BAFF-R targeting, CD20 depletion, TLR7/8 inhibition, plasma-cell targeting, and IFN pathway inhibition will separate by organ domain or remain parallel options without a clear hierarchy



• **Sjögren's disease will move from symptom control to disease-modifying mechanism tests**

- Oral sessions will include anifrolumab in the ANISE phase IIa study, ianalumab NEPTUNUS-1/2 phase III results, telitacicept phase III data, and nipocalimab biomarker-driven DAHLIAS analyses. The competitive question will consider whether IFN blockade, BAFF-R inhibition, BAFF/APRIL inhibition, or FcRn blockade will show systemic disease impact beyond dryness and glandular endpoints.





- **PsA and axSpA will pressure-test sequencing across IL-17A/F, IL-23, JAK, and TNF strategies**

- BE BOLD will compare bimekizumab directly with risankizumab in active PsA, while axSpA sessions will include sonelokimab, filgotinib, ivarmacitinib, gecacitinib, tofacitinib, and ROC-SpA data comparing IL-17A inhibitors with TNF-inhibitor cycling after first TNF failure. The open question will explore whether switching mechanism will outperform class cycling in practice



- **RA innovation will shift toward selective pathway control and immune-reset approaches**

- RA oral sessions will include zemprocitinib, balinatunfib, rosnilimab, tocilizumab versus abatacept, methotrexate strategy, etanercept for predicted poor methotrexate responders, and CD19 CAR-T in ACPA-positive refractory RA. The sessions will assess whether these approaches will change treatment selection or mainly add options for difficult-to-treat populations





(3/3)



- **Cell therapy will move from lupus proof-of-concept into a multi-disease category risk**

- EULAR will include obe-cel in severe refractory SLE, universal CAR-T 19 in systemic sclerosis, rese-cel in idiopathic inflammatory myopathy, and CD19 CAR-T in ACPA-positive refractory RA. The focus will examine whether immune reset will show durability and safety sufficient to challenge chronic biologic or oral therapy models



- **ILD, fibrosis, and pain/inflammation separation will become competitive workflow battlegrounds**

- MSD and Boehringer Ingelheim sessions will focus on SARD/SSc-ILD recognition, CTD-ILD monitoring, HRCT workflows, immune–fibrotic crosstalk, systemic sclerosis diagnosis, prognosis, and intervention. At the same time, UCB and Novartis SpA sessions will separate patient-reported symptom control from imaging-confirmed inflammation, creating a treatment-decision tension beyond response scores



Key Sessions To Watch (1/2)

Date	Session Title (short)	Type	Author / Institution	Why Watch
03 Jun 2026	Ianalumab NEPTUNUS in Sjögren's	Oral Abstract Session	Xavier Mariette / Le Kremlin Bicetre, France	Tests whether BAFF-R blockade can support a disease-modifying Sjögren's claim
03 Jun 2026	Telitacicept in Sjögren's	Oral Abstract Session	Dong Xu / Beijing, China	Phase 3 BAFF/APRIL data could intensify B-cell pathway competition
04 Jun 2026	Zemprocitinib in RA	Oral Abstract Session	Xiaofeng Zeng / China	Phase III oral therapy readout in moderate-to-severe active RA
04 Jun 2026	Balinatunfib in RA	Oral Abstract Session	Iain B. McInnes / Glasgow, UK	Selective TNFR1 signaling tests a narrower alternative to conventional anti-TNF biology
05 Jun 2026	Universal CAR-T 19 in SSc	Oral Abstract Session	FEI SUN / Tianjin, China	Extends autoimmune CAR-T question into systemic sclerosis
05 Jun 2026	REGENCY: obinutuzumab in lupus nephritis	Oral Abstract Session	Richard A. Furie / Great Neck, USA	Tissue-level B-cell depletion could raise the bar for LN differentiation
05 Jun 2026	Obe-cel CAR-T in refractory SLE	Oral Abstract Session	Maria Leandro / London, UK	Early CAR-T safety, PK, biomarker, and efficacy signal in severe refractory SLE
06 Jun 2026	BE BOLD: bimekizumab vs risankizumab in PsA	Late-breaking oral	Joseph F Merola / Dallas, USA	Directly tests IL-17A/F blockade against IL-23 inhibition in active PsA

Key Sessions To Watch (2/2)

Date	Session Title (short)	Type	Author / Institution	Why Watch
06 Jun 2026	Sonelokimab in axSpA	Late-breaking oral	Xenofon Baraliakos / Herne, Germany	Tests IL-17A/F Nanobody biology with PET and MRI-supported axial disease readouts
06 Jun 2026	Nipocalimab in SLE	Late-breaking oral	Richard A. Furie / Great Neck, USA	First FcRn proof-of-concept signal in SLE against established SLE mechanisms

Industry-Sponsored Sessions & Focus Areas – EULAR 2026





EULAR 2026– Competitive Landscape at a Glance (1/2)

Name	Sessions	Companies / Assets	Why It Matters
SLE and lupus nephritis immune targeting	Multiple	Nipocalimab, ianalumab, obinutuzumab, enpatoran, daratumumab, anifrolumab, sirolimus, obe-cel	SLE sessions will test whether mechanisms separate by organ domain, steroid-sparing effect, tissue response, and immune-reset durability
Sjögren's disease systemic therapy	Multiple	Anifrolumab, ianalumab, telitacicept, nipocalimab, BAFF/APRIL pathway	Sjögren's is becoming a disease-modifying therapy test case across IFN, B-cell, BAFF/APRIL, and FcRn mechanisms
PsA and axSpA sequencing	Multiple	Bimekizumab, risankizumab, sonelokimab, filgotinib, ivarmacitinib, gecacitinib, tofacitinib, guselkumab, secukinumab	Direct and indirect comparisons could influence whether clinicians switch mechanisms or cycle within established biologic classes
RA oral and upstream mechanisms	Multiple	Zemprocitinib, balinatumab, rosnilimab, tocilizumab, abatacept, etanercept, methotrexate, CD19 CAR-T	RA sessions will test whether selective signaling and cell-directed approaches can shift decision-making beyond standard b/tsDMARD sequencing



EULAR 2026– Competitive Landscape at a Glance (2/2)

Name	Sessions	Companies / Assets	Why It Matters
Autoimmune CAR-T and immune reset	Multiple	Obe-cel, rese-cel, universal CAR-T 19, CD19 CAR-T in RA	Cell therapy sessions will test whether immune reset becomes a repeatable rheumatology strategy or remains confined to refractory niches
SSc / CTD-ILD and fibrosis workflows	Multiple	Boehringer Ingelheim, MSD, nerandomilast, HRCT, SARD/SSc-ILD, CTD-ILD	ILD sessions are shifting attention toward earlier detection, imaging-based monitoring, and cross-specialty workflow control
Vasculitis, PMR, and glucocorticoid-sparing care	Multiple	Baricitinib, upadacitinib, mepolizumab, tocilizumab, rituximab, methotrexate	The clinical tension is whether targeted agents can reduce steroid dependence without introducing new safety trade-offs
AI, imaging, and digital decision support	Multiple	AI thermography, ADMIRA MRI, STED ANA pattern ML, digital RA education, salivary gland AI	AI content is concentrated around diagnostic accuracy, imaging interpretation, pathology scoring, and patient education workflows



Key Industry-Sponsored Sessions at EULAR 2026 (1/5)

✓ • **AstraZeneca:**

- Focus Areas: IFN Pathway, SLE Disease Control & Organ Damage Prevention
- Sessions on IFN pathway targeting, rapid disease control, remission, dermatology–rheumatology collaboration, and organ damage signal a push to make early SLE intervention the core competitive frame

✓ • **GSK:**

- Focus Areas: Lupus, Lupus Nephritis, EGPA & VEXAS
- Focus will be on atypical SLE, lupus progression, LN damage prevention, EGPA recognition, and VEXAS signal prioritization of severe systemic inflammatory disease and earlier intervention

✓ • **UCB / Biogen:**

- Focus Areas: SLE Treat-to-Target & Women of Child-bearing Age
- Sessions will frame SLE around treatment goals, risk-benefit trade-offs, and reproductive-age decision-making, suggesting a strategy focused on practical treatment barriers rather than only efficacy endpoints



Key Industry-Sponsored Sessions at EULAR 2026 (2/5)



• **MSD:**

- Focus Areas: Immuno-fibrotic Cross-talk, SARD/SSc-ILD, RA & PsA Biology
- Sessions will signal a fibrosis-and-stromal biology narrative across SARD/SSc-ILD, RA, PsA transition biology, biomarkers, and imaging-based clinical decision-making



• **Boehringer Ingelheim:**

- Focus Areas: Autoimmune ILD, CTD-ILD & Systemic Sclerosis Workflows
- Topics will emphasise case-based MDT management, ERS/EULAR guidance application, HRCT monitoring, systemic sclerosis diagnosis, prognosis, and intervention timing



• **AbbVie:**

- Focus Areas: RA Treatment Choice, GCA Remission & SpA Multidisciplinary Care
- Topics will include the defence of treatment-choice leadership across RA, GCA steroid-sparing care, early axSpA diagnosis, and extra-musculoskeletal SpA management



Key Industry-Sponsored Sessions at EULAR 2026 (3/5)

- **Novartis:**

- Focus Areas: Sjögren's, FMF, PsA and axSpA Treat-to-Target
- Sessions will be positioned on subclinical inflammation, Sjögren's disease activity, PsA/axSpA treatment success, and the pain-versus-inflammation debate as treat-to-target decision problems

- **Johnson & Johnson:**

- Focus Areas: Psoriatic Disease Spectrum
- The psoriatic disease session will signal an integrated disease-spectrum narrative, likely aimed at connecting skin, joint, and systemic burden rather than presenting PsA as an isolated joint condition

- **UCB:**

- Focus Areas: SpA Remission Gap and RA Bone Burden
- Sessions will contrast symptom-level remission with unresolved inflammation in SpA and link RA with hidden bone burden, widening the discussion beyond conventional disease activity scores



Key Industry-Sponsored Sessions at EULAR 2026 (4/5)



• **Amgen:**

- Focus Areas: CD19+ B-cell Targeting in IgG4-related Disease
- The IgG4-RD session will showcase the intent to frame CD19+ B-cell targeting as a long-term disease-control strategy rather than a flare-management tool



• **Merck:**

- Focus Areas: TLR7/8 Inhibition in Lupus
- The TLR7/8 lupus session will highlight an attempt to challenge whether upstream innate immune modulation can compete against IFN and B-cell pathway strategies



• **Vor Bio:**

- Focus Areas: BAFF/APRIL Biology in Sjögren's Disease
- The session will focus on upstream B-cell dysregulation and positions Sjögren's as a systemic immunology opportunity; asset ownership attribution should be checked post-congress



Key Industry-Sponsored Sessions at EULAR 2026 (5/5)

- **Bristol Myers Squibb:**

- Focus Areas: CAR T Immune Reset in SLE and SSc
- Presentations will show autoimmune disease trajectories and CAR T perspectives, signalling a push to keep immune reset visible in rheumatology beyond oncology-derived treatment logic

- **Cabaletta Bio:**

- Focus Areas: CAR T Therapy for Autoimmune Diseases
- The CAR T-focused session will emphasise continued category-building around cellular therapy for refractory autoimmune disease, with unresolved durability and safety benchmarks

- **Eli Lilly:**

- Focus Areas: Obesity and Psoriatic Disease
- Sessions will frame obesity as a mechanistic and management variable in PsA, reinforcing that comorbidity control may become part of treatment differentiation.



New Entrants

Asset / Company	2026 Presence
Balinatunfib	Oral Abstract Session: Oral TNFR1 signal inhibitor in moderate-to-severe rheumatoid arthritis, SPECIFI-RA phase 2b
Zemprocitinib / LNK01001	Oral Abstract Session: :Randomized phase III trial in moderate-to-severe active rheumatoid arthritis
Rosnilimab	Oral Abstract Session: Selective pathogenic T-cell depletion in RENOIR phase 2b RA plus translational analysis
Nipocalimab	Late-breaking oral Session: FcRn blockade proof-of-concept in phase 2 JASMINE-SLE; biomarker-driven DAHLIAS in Sjögren's
Telitacicept	Oral Abstract Session: Phase 3 randomized study in Sjögren's disease
Obe-cel	Oral Abstract Session: CD19 CAR-T therapy in severe refractory SLE
Rese-cel	Oral Abstract Session: CAR-T therapy in severe refractory idiopathic inflammatory myopathy
Sonelokima	Late-breaking oral: IL-17A/F-inhibiting Nanobody in axial spondyloarthritis with PET/MRI support
Zasocitinib / TAK-279	Oral Abstract Session: Selective TYK2 inhibitor biomarkers in active psoriatic arthritis
HR091506	Late-breaking oral Session: Extended-release tablets in gout, hyperuricemia, recurrent flares, tophi, or chronic gouty arthropathy







AI / Digital Health Angle at EULAR 2026 (1/2)

- **AI/ML presentations at EULAR 2026 will represent a practical rheumatology workflow signal, not a broad digital-health theme. Sessions focusing on AI-enabled imaging, early diagnosis, EHR-based disease detection, flare prediction, and patient-facing tools will test whether computational approaches can accelerate referral, diagnosis, monitoring, and care prioritization**
- **AI/ML activity at EULAR 2026 will be strategically relevant because it will target rheumatology bottlenecks where clinical assessment is subjective or capacity-limited. The main signal will be whether these tools can move from validation into workflows that support earlier referral, objective inflammation assessment, disease-risk prediction, and longitudinal patient monitoring**
- **Key sessions will include:**
 - Artificial Intelligence-Based Thermographic Detection of Joint Inflammation in Rheumatoid Arthritis
 - Automatic Deep learning-based MRI analysis of Inflammatory signs in RA (ADMIRA)
 - Robot-assisted arthrosonography (ARTHUR) with AI analysis (DIANA)
 - Using Machine Learning and Electronic Health Records for Early Identification of ANA-related Connective Tissue Diseases



AI / Digital Health Angle at EULAR 2026 (2/2)

- The Use of Artificial Intelligence to Recognize Facial Features of Systemic Sclerosis
- RheumaPredict: Externally Validated Ensemble Machine Learning Model for Predicting Rheumatoid Arthritis Flares
- **Sessions will suggest AI and digital tools will be applied to improve:**
 - Earlier patient identification in ANA-related connective tissue diseases, systemic sclerosis, Behçet's syndrome, RA, PsA, and axSpA
 - Objective inflammation assessment through AI thermography, AI-supported ultrasound, MRI interpretation, radiographic progression analysis, and salivary gland imaging
 - Disease monitoring and risk prediction through RA flare prediction, RA remission prediction, gout flare prediction, anti-CCP progression modeling, and SSc-ILD airway prognostic assessment
 - Patient engagement through AI-personalized exercise in juvenile idiopathic arthritis, multilingual axSpA advocacy, wearable-derived quality-of-life prediction, and AI-readiness surveys
 - Evidence generation through EHR-based machine learning platforms designed to emulate randomized trials after methotrexate failure in RA



What We're Watching for Post-EULAR 2026

- Whether BE BOLD bimekizumab versus risankizumab creates a usable PsA differentiation claim, especially around joint endpoints, onset, and IL-17A/F safety trade-offs
- Whether nipocalimab, ianalumab, obinutuzumab, enpatoran, daratumumab, sirolimus, anifrolumab, and obe-cel begin to separate by SLE organ domain, steroid-sparing effect, biomarker-defined patients, and durability
- Whether ianalumab NEPTUNUS, telitacicept phase 3, nipocalimab DAHLIAS, and anifrolumab ANISE data clarify which Sjögren's mechanisms can support disease-modifying positioning
- Whether sonelokimab, filgotinib, ivarmacitinib, gecacitinib, tofacitinib, IL-17A inhibitors, and TNF cycling data clarify axSpA sequencing after inadequate TNF response
- Whether obe-cel, rese-cel, universal CAR-T 19, and CD19 CAR-T in RA show enough safety and durability signals to move autoimmune cell therapy beyond refractory-use discussion
- Whether AI thermography, ADMIRA MRI, STED ANA ML, digital RA education, and RA remission-prediction sessions provide implementation evidence rather than only model performance



Strategic Insights and Strategy Development is our focus

COMPETITIVE STRATEGY
AND INTELLIGENCE



DIGITAL HEALTH, ARTIFICIAL
INTELLIGENCE AND IoE



GENE & CELL THERAPY



VACCINES & INFECTIOUS
DISEASES



INVESTMENT INSIGHTS

e: INFO@LQVENTURES.COM

w: WWW.LQVENTURES.COM